Clinical Trials Browser

Phase 2 × Ovariancancer × 90 days × Clear all

NCT07339553 2026-01-21

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Phase 2 Not yet recruiting

Ovariancancer